PALI
Neutral signalScored 2026-08-03 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Palisade Bio, Inc.
- Nom
- Palisade Bio, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $231.8M
- Employés
- 14
- PDG
- J. D. Finley
- Site web
- https://www.palisadebio.com
- Marché
- ASBPATHABCTXCRISCTXRDARE
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 125000 titres (~250182 USD) VENTE TOTALE: 198678 titres (~409879 USD)
- Insiders
- Baltera Robert Jr.Finley John DavidJones Mitchell Lawrence
- Total bought
-
$250,182
Avg buy (VWAP, 90d window) $1.44 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-07-09
- Last synced
-
2026-10-20 00:36:23
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-02 | Williams Donald Allen | Buy · P | 10,000 | $1.46 | $14,600 | Form 4 |
| 2026-10-01 | Williams Donald Allen | Buy · P | 10,000 | $1.42 | $14,200 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-08-03 Drivers: fundamentals. Moteurs : fondamentaux.
PALI presents a speculative event-driven setup anchored by a genuine FDA IND clearance for PALI-2108 and bullish sell-side initiation, but the fundamental backdrop is critically weak — zero revenue, persistent cash…
The first sentence of the analysis written for PALI on 2026-08-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Neutral signal
Drivers: fundamentals. Moteurs : fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 28.95 · operating margin 0.0%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 100.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | -4914.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | -4912.4% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | -5228.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | -4920.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | -4920.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | -4920.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | -4926.4% | 0.0% | 0.0% | |
| Current Ratio | 28.952 | 3.243 | 5.154 | 4.891 | 4.610 | |
| Quick Ratio | 28.952 | 3.243 | 5.154 | 4.891 | 4.610 | |
| Solvency Ratio | -3.380 | -4.261 | -4.489 | -4.341 | -5.171 | |
| Cash Ratio | 28.772 | 3.035 | 4.807 | 4.111 | 4.205 | |
| Price To Earnings Ratio | -7.833 | -0.162 | -0.328 | -4.719 | -0.455 | |
| Price To Earnings Growth Ratio | 0.081 | 0.003 | -0.005 | 0.048 | -0.000 | |
| Forward Price To Earnings Growth Ratio | 0.081 | 0.003 | -0.005 | 0.048 | -0.000 | |
| Price To Earnings Diluted Ratio | -7.833 | -0.162 | -0.328 | -4.719 | -0.383 | |
| Price To Earnings Diluted Growth Ratio | 0.081 | 0.003 | -0.005 | 0.047 | -0.000 | |
| Price To Book Ratio | 1.011 | 0.312 | 0.357 | 5.501 | 1.643 | |
| Price To Sales Ratio | 0.000 | 0.000 | 16.143 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -12.061 | -0.192 | -0.362 | -5.134 | -0.819 | |
| Price To Operating Cash Flow Ratio | -12.061 | -0.192 | -0.363 | -5.138 | -0.819 | |
| Debt To Assets Ratio | 0.001 | 0.016 | 0.026 | 0.026 | 0.016 | |
| Debt To Equity Ratio | 0.001 | 0.023 | 0.033 | 0.032 | 0.027 | |
| Debt To Capital Ratio | 0.001 | 0.022 | 0.032 | 0.031 | 0.026 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.038 | 1.452 | 1.242 | 1.263 | 1.699 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.022 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -2.340 | -3.768 | -4.305 | -4.436 | -5.919 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | -44.532 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.000 | 1.001 | 1.000 | |
| Debt Service Coverage Ratio | -207.012 | -158.495 | -70.988 | -141.030 | -9.745 | |
| Interest Coverage Ratio | -1,805.600 | -1,238.250 | -871.333 | -1,209.308 | -17.454 | |
| Short Term Operating Cash Flow Coverage Ratio | -152.775 | -154.342 | -70.462 | -151.818 | -169.805 | |
| Operating Cash Flow Coverage Ratio | -152.775 | -72.148 | -30.171 | -33.069 | -74.236 | |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | -2,783.250 | -1,336.000 | 0.000 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | -2,783.250 | -1,336.000 | 0.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 0.148 | 0.507 | 0.654 | -3.978 | -0.075 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | ▼-20.0% |
| Ebit Margin | 0.0% | 0.0% | ▲982.8% |
| Ebitda Margin | 0.0% | 0.0% | ▲982.5% |
| Operating Profit Margin | 0.0% | 0.0% | ▲1045.6% |
| Pretax Profit Margin | 0.0% | 0.0% | ▲984.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | ▲984.0% |
| Net Profit Margin | 0.0% | 0.0% | ▲984.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | ▲985.3% |
| Current Ratio | 28.952 | ▲25.709 | ▲19.582 |
| Quick Ratio | 28.952 | ▲25.709 | ▲19.582 |
| Solvency Ratio | -3.380 | ▲0.881 | ▲0.948 |
| Cash Ratio | 28.772 | ▲25.737 | ▲19.786 |
| Price To Earnings Ratio | -7.833 | ▼-7.671 | ▼-5.134 |
| Price To Earnings Growth Ratio | 0.081 | ▲0.078 | ▲0.056 |
| Forward Price To Earnings Growth Ratio | 0.081 | ▲0.078 | ▲0.056 |
| Price To Earnings Diluted Ratio | -7.833 | ▼-7.671 | ▼-5.148 |
| Price To Earnings Diluted Growth Ratio | 0.081 | ▲0.078 | ▲0.056 |
| Price To Book Ratio | 1.011 | ▲0.699 | ▼-0.754 |
| Price To Sales Ratio | 0.000 | 0.000 | ▼-3.229 |
| Price To Free Cash Flow Ratio | -12.061 | ▼-11.869 | ▼-8.347 |
| Price To Operating Cash Flow Ratio | -12.061 | ▼-11.869 | ▼-8.346 |
| Debt To Assets Ratio | 0.001 | ▼-0.015 | ▼-0.016 |
| Debt To Equity Ratio | 0.001 | ▼-0.022 | ▼-0.022 |
| Debt To Capital Ratio | 0.001 | ▼-0.021 | ▼-0.022 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.038 | ▼-0.414 | ▼-0.301 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | ▼-0.004 |
| Operating Cash Flow Ratio | -2.340 | ▲1.428 | ▲1.814 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | ▲8.906 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 0.000 | ▼-0.000 |
| Debt Service Coverage Ratio | -207.012 | ▼-48.518 | ▼-89.558 |
| Interest Coverage Ratio | -1805.600 | ▼-567.350 | ▼-777.211 |
| Short Term Operating Cash Flow Coverage Ratio | -152.775 | ▲1.567 | ▼-12.934 |
| Operating Cash Flow Coverage Ratio | -152.775 | ▼-80.627 | ▼-80.295 |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | ▲823.850 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | ▲823.850 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 0.148 | ▼-0.359 | ▲0.697 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $130.8M | $2.3M | $4.0M | $68.6M | $12.1M | |
| Enterprise value | -$2.5M | -$7.3M | -$8.0M | $56.7M | $1.8M | |
| EV / Sales | 0.00x | 0.00x | -32.11x | 0.00x | 0.00x | |
| EV / Op. cash flow | 0.23x | 0.60x | 0.72x | -4.24x | -0.12x | |
| EV / Free cash flow | 0.23x | 0.60x | 0.72x | -4.24x | -0.12x | |
| EV / EBITDA | 0.15x | 0.51x | 0.65x | -3.98x | -0.07x | |
| Net debt / EBITDA | 7.95x | 0.67x | 0.98x | 0.84x | 0.42x | |
| Current ratio | 28.95x | 3.24x | 5.15x | 4.89x | 4.61x | |
| Income quality | 0.65x | 0.84x | 0.91x | 0.94x | 0.56x | |
| Graham net-net | $2 | $5 | $21 | $12 | $440 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.1% | 100.1% | 100.1% | 100.1% | 109.9% | |
| Working capital | $129.6M | $7.3M | $10.7M | $11.7M | $9.0M | |
| Invested capital | $129.6M | $7.3M | $10.9M | $12.0M | $9.1M | |
| Return on assets | -12.5% | -132.7% | -87.5% | -90.5% | -212.7% | |
| Operating ROA | -24.9% | -119.2% | -87.7% | -111.2% | -539.0% | |
| Return on tangible assets | -12.5% | -132.7% | -87.5% | -90.5% | -212.7% | |
| Return on equity | -13.0% | -192.7% | -108.7% | -114.3% | -361.4% | |
| Return on invested capital | -13.9% | -190.8% | -111.3% | -121.5% | -409.7% | |
| Return on capital employed | -13.9% | -194.4% | -114.0% | -123.3% | -417.9% | |
| Earnings yield | -12.8% | -618.0% | -304.8% | -20.8% | -219.9% | |
| Free cash flow yield | -8.3% | -521.9% | -276.0% | -19.5% | -122.1% | |
| Capex / Op. cash flow | 0.0% | 0.0% | -0.0% | -0.1% | 0.0% | |
| Capex / Depreciation | 0.0% | 0.0% | 100.0% | 333.3% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 1.6% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 2480.8% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 2757.2% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 249.6% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 216d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 216d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 216d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+5499.4%EV / Sales n/aEV / EBITDA ▼-70.7%EV / Op. cash flow ▼-0.370Earnings yield ▲+6.051
Profitability
Return on equity ▲+1.797Return on assets ▲+1.202Return on invested capital ▲+1.769Return on capital employed ▲+1.805Operating ROA ▲+0.943Income quality ▼-0.198Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+25.709Net debt / EBITDA ▲+7.281Working capital ▲+122327000.000Invested capital ▲+122240000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+981.0%EV / Sales n/aEV / EBITDA ▲+299.0%EV / Op. cash flow ▲+0.352Earnings yield ▲+2.071
Profitability
Return on equity ▲+3.484Return on assets ▲+2.002Return on invested capital ▲+3.958Return on capital employed ▲+4.040Operating ROA ▲+5.141Income quality ▲+0.091Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+24.342Net debt / EBITDA ▲+7.525Working capital ▲+120575000.000Invested capital ▲+120463000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Recent news
- 2026-10-12 Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026 Five presentations connect targeted intestinal exposure and sustained systemic drug exposure with PDE4 target engagement and early clinical activity, supporting ongoing Phase 2 development Two presentations selected for ACG Presidential Poster Awards, a distinction received by approximately 5% of accepted abstracts Microbiome and transcriptomic analyses support the delivery platform and a potential precision medicine approach Denver, CO, Oct.
- 2026-10-03 Palisade Bio, Inc. (NASDAQ:PALI) Stock Has Average Target Price of $9.83 According to Analysts Palisade Bio, Inc. (NASDAQ: PALI - Get Free Report) has been given a consensus rating of "Buy" by the ten ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating
- 2026-09-28 Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn''s Disease at UEG Week 2026 Oral presentation to highlight early endoscopic improvement and evidence of PDE4 target engagement in fibrostenotic Crohn''s disease
- 2026-09-28 Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’s Palisade Bio (NASDAQ: PALI) said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative colitis and Crohn''s disease after completing its Phase I program. Chief Executive Officer JD Finley said PALI-2108 is a once-daily oral phosphodiesterase 4, or PDE4, inhibitor designed as a prodrug that is bioactivated in the terminal ileum
- 2026-09-27 Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn''s Palisade Bio NASDAQ: PALI said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative colitis and Crohn''s disease after completing its Phase I program.
- 2026-09-23 Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance Canadian clearance supports site activation and enrollment in the global study of once-daily oral PALI-2108 Primary efficacy results from approximately 204 patients with moderately to severely active ulcerative colitis expected in the second half of 2027 Denver, CO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that Health Canada has cleared the Company''s Clinical Trial Application (CTA) for ASCENTRA-UC, its global Phase 2 study evaluating PALI-2108 in patients with moderately to severely active ulcerative colitis (UC).
- 2026-09-22 Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn''s Disease, Expanding Phase 2 Development Across IBD ASCENTRA-CD expected to enroll approximately 60 patients with moderate to severe Crohn''s disease First patient dosing targeted for Q1 2027; primary efficacy readout (Week 12 endoscopic response) targeted for Q1 2028 Phase 2 program builds on clinical experience in fibrostenotic Crohn''s disease demonstrating targeted tissue exposure, PDE4 target engagement and encouraging endoscopic activity Denver, CO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company''s Investigational New Drug (IND) application for PALI-2108, enabling initiation of the Phase 2 ASCENTRA-CD clinical trial in patients with moderate to severe Crohn''s disease (CD).
- 2026-09-21 Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum Presentation scheduled for September 23, 2026 at 1:00 PM ET Access the webcast here Denver, CO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that JD Finley, Chief Executive Officer, and Mitchell Jones, M.D.
- 2026-09-16 Palisade Bio, Inc. (PALI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Palisade Bio, Inc. (PALI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-03 Palisade Bio to Participate in Upcoming Investor Conferences Denver, CO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that members of management will participate in three healthcare investor conferences in September 2026.